2024 Part B Step Therapy program

Effective for fill dates on or after Jan. 1, 2024, the following coverage requirements will apply to the Part B Step Therapy program.

  • The following new categories will be added to the Part B Step Therapy program:
    • Acromegaly
    • Antiemetics
    • Bone Resporption Inhibitors
    • Botulinum Toxins
  • The following existing categories will be updated: 
    • Gaucher’s Disease 
    • Leucovorin/LEVOleucovorin Injection 
    • Trastuzumab – Ogivri will be a non-preferred product. Kanjinti and Trazimera will be the preferred trastuzumab products.

For more information, refer to the updated Medicare Part B Step Therapy Medical Necessity Guidelines.